Sign Up for Free!

Continue Analyzing the page and more.

Already have an Account? Log In

The Trial has ended

Continue Analyzing the page and more.

Eton Pharmaceuticals Inc logo
ETON

Eton Pharmaceuticals Inc

MaveScore 38 Low model confidence
Last Price US$32.14 As of Jun 15, 2026
Market Cap US$881.6m Company size context
7D Performance 7.35% Past 7 days
1Y Performance 69.78% Past 12 months
Model Rating
Historical model output for research review

Fundamental data date

Dec 31, 2025

167 days old

Market price date

Jun 15, 2026

1 day old

Coverage

16/16

No missing model inputs

Data quality

Excellent

Current stored snapshot

Transparent research score

Why the model scores this stock

MaveScore is a research prioritization score from 0 to 100. It is historical model output for watchlist review, not personalized financial advice.

MaveScore 38 Low confidence

Stored data quality

Freshness and coverage checks

Latest stored fundamentals and price inputs are recent enough for normal research review.

16/16 Current stored snapshot

Quality

Quality score blends the latest weighted model rank with underlying profitability and dilution ranks.

15/35 Weak

Financial Strength

Financial strength rewards durable profitability, margins, and positive free cash flow.

8/25 Weak

Valuation Support

Valuation favors positive earnings, positive cash flow, and lower price-to-book multiples.

0/15 Weak

Momentum

Momentum highlights research candidates with supportive 3-month and 6-month price regimes.

15/15 Strong

Shareholder Alignment

Shareholder alignment rewards less dilutive share behavior and enough size for liquid research coverage.

0/10 Weak

Positive model output

  • Momentum highlights research candidates with supportive 3-month and 6-month price regimes.

Research risks to review

  • Quality score blends the latest weighted model rank with underlying profitability and dilution ranks.
  • Financial strength rewards durable profitability, margins, and positive free cash flow.
  • Valuation favors positive earnings, positive cash flow, and lower price-to-book multiples.

MaveScore uses historical model inputs, stored company fundamentals, and stored price context for research support only. Review missing inputs and business-specific risks before acting.

Dashboard Funda..tals Deep..lue Prediction Screener Map

Eton Pharmaceuticals Inc Overview

Industry: Drug Manufacturers Specialty & Generic

Sector: Healthcare

Eton Pharmaceuticals, Inc., a specialty pharmaceutical company, focuses on developing, acquiring, and commercializing pharmaceutical products for rare diseases. The company offers ALKINDI SPRINKLE, a replacement therapy for adrenocortical insufficiency in children under 17 years of age; Carglumic Acid for the treatment of acute and chronic hyperammonemia due to N-acetylglutamate Synthase deficiency; Betaine Anhydrous for the treatment of homocystinuria; and dehydrated alcohol injection to treat methanol poisoning. It also provides Zeneo hydrocortisone autoinjector for the treatment of adrenal crisis; Alaway Preservative Free, a preservative-free ophthalmic product to treat allergic conjunctivitis; EPRONTIA, a liquid formulation of topiramate; ZONISADE, a liquid formulation of zonisamide for the treatment of partial seizures in patients with epilepsy; and Lamotrigine for Oral Suspension for the treatment of epilepsy. Eton Pharmaceuticals, Inc. was incorporated in 2017 and is based in Deer Park, Illinois.

Eton Pharmaceuticals Inc is evaluated using Mavefund's quality framework: growing earnings, durable profit margins, conservative leverage, strong return on equity, and disciplined share repurchases.

Score

Price History & Performance

Review Eton Pharmaceuticals Inc in context before unlocking the interactive price chart, financial overlays, and downloadable ratio tables.

Recent News



Eton Pharmaceuticals Inc Competitors

Eton Pharmaceuticals Inc operates in the Drug Manufacturers Specialty & Generic industry within the Healthcare sector. Unlock the full page to compare peer rankings, valuation quality, profitability, leverage, and growth trends.

Earnings Per Share

EPS quality is one of the core Mavefund signals. Sign up to continue into the detailed EPS, ROE, margin, share buyback, leverage, and financial ratio analysis.

Continue the analysis

Sign up to unlock ROE, net margin, share buyback, leverage, financial ratios, peer charts, and downloads.

View plans
Ticker Image

Eton Pharmaceuticals Inc

US$32.14

US$881.6m

7.35%

69.78%